UPDATE: Jefferies & Company Reiterates Buy Rating, Raises PT on Mindray Medical International
In a report published Wednesday, Jefferies & Company reiterated its Buy rating on Mindray Medical International (NYSE: MR), and raised its price target from $34.00 to $36.00.
Jefferies noted, “MR put up a mixed 3Q with a drastic slowdown in PMLS, a sequential stepback in the margin profile, but in-line non-GAAP EPS. Language regarding deterioration in developed markets, abrupt CEO change, and still unresolved supplier dispute leave lingering questions but overall growth profile still among upper tier.”
Mindray Medical International closed on Tuesday at $31.90.
Latest Ratings for MR
|Nov 2015||Standpoint Research||Downgrades||Buy||Hold|
|Jun 2015||JMP Securities||Upgrades||Underperform||Market Perform|
|Mar 2015||Credit Suisse||Downgrades||Neutral||Underperform|
© 2017 Benzinga.com. Benzinga does not provide investment advice. All rights reserved.